Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival and Mortality in Promyelocytic Leukemia

Are rates the same in sAPL and de novo APL?

Publish date:: July 29, 2015

There is no difference in overall survival (OS) or early mortality rate between secondary acute promyelocytic leukemia (sAPL) and de novo APL, according to a study of 90 patients with sAPL and 1600 patients with de novo APL. Researchers found:

• Patients with sAPL were more likely than patients with de novo APL to be older, White, and diagnosed after 2005.

• Mortality rate at 1 month (28.9% vs 23.0%) and 5-year OS 42% vs 50%) were similar between sAPL and de novo APL.

• sAPL was associated with similar OS as de novo APL (hazard ratio, 1.11).

Citation: Giri S, Pathak R, Martin MG, Bhatt VR. Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. [Published online ahead of print July 25, 2015]. Leuk Lymphoma. doi:10.3109/10428194.2015.1063142.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,